Analogs and fibrosis regression in hepatitis B

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Nucleoside or nucleotide analogs (NUCs) are effective antiviral treatments for chronic hepatitis B virus (HBV) infection.
• NUCs demonstrate significant improvements in liver fibrosis, even with short-term treatment.
• Liver fibrosis regression is a key outcome in managing chronic HBV.

Purpose of the Study:

• To evaluate the efficacy of various NUCs in improving liver fibrosis in hepatitis B patients.
• To compare fibrosis regression rates among different NUCs in HBeAg-positive and HBeAg-negative patients.
• To assess the impact of long-term NUC treatment and drug resistance on liver fibrosis.

Main Methods:

• Analysis of fibrosis regression data from HBeAg-positive and HBeAg-negative patients treated with different NUCs (lamivudine, adefovir, telbivudine, entecavir, tenofovir).
• Assessment of fibrosis improvement after 1 year of treatment and over longer durations.
• Consideration of the role of non-invasive fibrosis diagnosis methods.

Main Results:

• After one year, significant fibrosis improvement was observed across multiple NUCs, with rates ranging from 35% to 74% in HBeAg-positive and 36% to 71% in HBeAg-negative patients.
• Long-term NUC therapy showed continued improvement, reaching up to 63% for lamivudine and 71% for adefovir.
• Antiviral drug resistance can potentially hinder histological improvement despite NUC treatment.

Conclusions:

• NUCs are valuable for improving liver fibrosis in chronic HBV infection.
• Long-term treatment with NUCs can lead to sustained fibrosis regression, though drug resistance is a consideration.
• Non-invasive fibrosis markers are emerging as important tools for diagnosis and patient management in chronic HBV.